GLP-1 Safety Notice

GLP-1 receptor agonists including compounded semaglutide and tirzepatide are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Animal studies showed a potential increased risk of thyroid C-cell tumors; human relevance has not been confirmed. All prospective users should discuss risks and contraindications with their provider before beginning treatment.